Key Points
- Director Joseph Slattery sold 5,200 shares for $113,360 at an average $21.80, cutting his direct stake by 78% to 1,467 shares.
- Replimune reported a quarterly loss of $0.54 per share, narrower than analysts’ expected $0.78 loss; analysts forecast a $2.40 loss per share for the full year.
- Analysts’ consensus rating is Moderate Buy, with a $14.33 average price target. The stock opened at $23.28, near its 12-month high of $23.41.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) Director Joseph Slattery sold 5,200 shares of the business's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $21.80, for a total transaction of $113,360.00. Following the sale, the director directly owned 1,467 shares in the company, valued at approximately $31,980.60. This represents a 78.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Replimune Group Trading Up 4.6%
Shares of Replimune Group stock opened at $23.28 on Wednesday. The company has a current ratio of 7.11, a quick ratio of 6.90 and a debt-to-equity ratio of 0.59. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $23.41. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -8.34 and a beta of 0.93. The firm's 50 day simple moving average is $14.39 and its two-hundred day simple moving average is $9.82.
Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.24. Analysts predict that Replimune Group, Inc. will post -2.40 EPS for the current year.
Institutional Trading of Replimune Group
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Replimune Group in the 2nd quarter valued at $99,171,000. Montanova Capital LLC raised its holdings in shares of Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock worth $48,595,000 after purchasing an additional 168,000 shares during the last quarter. Opaleye Management Inc. acquired a new position in Replimune Group during the second quarter valued at $15,332,000. Dimensional Fund Advisors LP lifted its position in Replimune Group by 1.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company's stock valued at $8,719,000 after purchasing an additional 20,742 shares during the period. Finally, EcoR1 Capital LLC acquired a new position in Replimune Group during the first quarter valued at $7,650,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Replimune Group in a research note on Monday, October 5th. Wolfe Research raised Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. Wall Street Zen upgraded Replimune Group from a "sell" rating to a "hold" rating in a research note on Saturday, October 31st. Leerink Partners increased their price objective on Replimune Group from $19.00 to $31.00 and gave the company an "outperform" rating in a report on Thursday, October 29th. Finally, Piper Sandler upgraded Replimune Group from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $14.33.
Read Our Latest Report on Replimune Group
Replimune Group Company Profile
(
Get Free Report)
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company's investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
